Elizabeth Reczek
Amministratore Delegato presso Neutron Therapeutics, Inc.
Profilo
Elizabeth Reczek is currently the Chief Executive Officer & Director at Neutron Therapeutics, Inc. She was previously the President & Chief Executive Officer at Excelimmune, Inc. and the Chief Executive Officer & Director at SeqLL, Inc. Reczek received an undergraduate degree from Harvard University and a doctorate degree from Massachusetts Institute of Technology.
Posizioni attive di Elizabeth Reczek
| Società | Posizione | Inizio |
|---|---|---|
Neutron Therapeutics, Inc.
 Neutron Therapeutics, Inc. Medical DistributorsDistribution Services Neutron Therapeutics, Inc. is a private company that specializes in providing accelerator-based boron neutron capture therapy (BNCT) systems for targeted radiation therapy of solid tumors. The company is based in Danvers, MA and was founded in 2015 by Bill Buckley and Ted Smick. The company's flagship product, the Nubeam® therapy platform, is a compact, in-hospital neutron source that offers a higher neutron flux compared to competing systems and meets stringent reference values published by the International Atomic Energy Agency. Elizabeth Reczek has been the CEO of the company since 2020. | Amministratore Delegato | 14/12/2021 |
Precedenti posizioni note di Elizabeth Reczek
| Società | Posizione | Fine |
|---|---|---|
| ATLANTICPAR | Amministratore Delegato | - |
Excelimmune, Inc.
 Excelimmune, Inc. Miscellaneous Commercial ServicesCommercial Services Excelimmune, Inc. provides laboratory and biotechnology services. It is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. The firm’s next generation technology is applicable to the treatment of diseases and infections caused by common bacteria, disease-causing proteins and viral pathogens. The company was founded in 2006 by Quinton Y. Zondervan and Vincent W. Coljee and is headquartered in Lexington, MA. | Amministratore Delegato | - |
Formazione di Elizabeth Reczek
| Harvard University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ATLANTICPAR | Health Technology |
| Aziende private | 2 |
|---|---|
Excelimmune, Inc.
Excelimmune, Inc. Miscellaneous Commercial ServicesCommercial Services Excelimmune, Inc. provides laboratory and biotechnology services. It is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. The firm’s next generation technology is applicable to the treatment of diseases and infections caused by common bacteria, disease-causing proteins and viral pathogens. The company was founded in 2006 by Quinton Y. Zondervan and Vincent W. Coljee and is headquartered in Lexington, MA. | Commercial Services |
Neutron Therapeutics, Inc.
Neutron Therapeutics, Inc. Medical DistributorsDistribution Services Neutron Therapeutics, Inc. is a private company that specializes in providing accelerator-based boron neutron capture therapy (BNCT) systems for targeted radiation therapy of solid tumors. The company is based in Danvers, MA and was founded in 2015 by Bill Buckley and Ted Smick. The company's flagship product, the Nubeam® therapy platform, is a compact, in-hospital neutron source that offers a higher neutron flux compared to competing systems and meets stringent reference values published by the International Atomic Energy Agency. Elizabeth Reczek has been the CEO of the company since 2020. | Distribution Services |
- Borsa valori
- Insiders
- Elizabeth Reczek
